olivLaw · US equity research
Mirion Technologies, Inc. MIR
Measuring & Controlling Devices, NEC · SIC 3829 · Vertical: Measuring & Controlling Devices, NEC (SIC 3829)
Mirion Technologies is a global provider of products, services and software for radiation detection, measurement and monitoring, active in nuclear power, medicine and defense. Revenue grew 19.7% in the second quarter of 2026, in a setting where nuclear demand is increasingly linked to data centers and energy security. Fiscal 2025 revenue was 925.4 million USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Mirion Technologies, Inc. (MIR) stock was 17.97 USD (−5.67% on the day), with market capitalisation 336.9 m USD, P/E 159.4 on diluted EPS of 0.11 USD over the last 12 months, beta 1.58, 52-week range 14.12–28.55 USD. Latest reported quarter (Q3 2026): revenue of 277.8 m USD (+24.5% YoY), net income of 7.4 m USD (+155.2% YoY), diluted EPS 0.03 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 61.1
- strong (55–70)
- Bollinger (20, 2)
- 13.57 – 19.15
- in the upper half of the band · %B 0.79 · band width 34.1%
- SMA 50 / 200
- 15.90 / 18.17
- mixed trend
- MACD (12, 26, 9)
- 0.72 / 0.37
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +20.4% | −1.1% | +21.5 pp | — |
| 3 months | +16.6% | −0.5% | +17.1 pp | — |
| 6 months | −11.9% | +4.4% | −16.3 pp | — |
| Year to date | −23.3% | +12.3% | −35.6 pp | — |
| 1 year | −35.4% | +13.5% | −48.9 pp | −33.4% |
| 3 years | +119.4% | +76.4% | +43.0 pp | −9.9% |
| 5 years | +59.6% | +63.7% | −4.1 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 254.3 m | 202.0 m | 222.9 m | 223.1 m | 277.4 m | 257.6 m | 266.8 m | 277.8 m |
| Cost of revenue | 132.0 m | 105.9 m | 120.4 m | 118.6 m | 141.9 m | 138.5 m | 133.7 m | 146.3 m |
| Gross profit | 122.3 m | 96.1 m | 102.5 m | 104.5 m | 135.5 m | 119.1 m | 133.1 m | 131.5 m |
| Research & development | 8.1 m | 8.7 m | 10.0 m | 10.1 m | 10.1 m | 9.6 m | 10.1 m | 10.3 m |
| SG&A | 85.2 m | 78.7 m | 82.6 m | 87.0 m | 99.9 m | 105.8 m | 105.1 m | 104.0 m |
| Operating income | 29.0 m | 8.7 m | 9.9 m | 7.4 m | 25.5 m | 3.7 m | 17.9 m | 17.2 m |
| Depreciation & amortisation | 34.6 m | 33.7 m | 33.9 m | 34.9 m | 35.7 m | 40.8 m | 38.8 m | 38.2 m |
| Interest expense | 13.2 m | — | — | — | — | — | — | — |
| Pre-tax income | 15.7 m | 600.0 k | 7.8 m | 1.2 m | 23.1 m | -5.2 m | 11.3 m | 10.9 m |
| Income tax | -200.0 k | 200.0 k | -700.0 k | -1.9 m | 5.3 m | -1.8 m | 3.2 m | 3.1 m |
| Net income | 15.0 m | 300.0 k | 8.3 m | 2.9 m | 17.3 m | -3.4 m | 7.7 m | 7.4 m |
| Diluted EPS | 0.07 ≈ | 0.00 | 0.03 | 0.01 | 0.06 ≈ | -0.01 | 0.03 | 0.03 |
| Operating cash flow | 60.8 m | 35.6 m | 12.4 m ≈ | 22.3 m ≈ | 73.0 m | 18.9 m | 58.5 m ≈ | 59.2 m ≈ |
| Capex | 11.7 m | 8.5 m | 8.8 m ≈ | 9.3 m ≈ | 9.8 m | 9.5 m | 10.4 m ≈ | 11.9 m ≈ |
| Share repurchases | 0 | 18.6 m | 31.0 m ≈ | 0 ≈ | 0 | 16.0 m | 25.0 m ≈ | 55.8 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 17 percentile of its own 6-quarter history (min 125.2, median 205.0, max 694.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | 440.1 m | 478.2 m | 611.6 m | 717.8 m | 800.9 m | 860.8 m | 925.4 m |
| Revenue YoY | unavailable | unavailable | +8.7% | +27.9% | +17.4% | +11.6% | +7.5% | +7.5% |
| Net income | -295 | -341 | -45.3 m | -158.4 m | -276.9 m | -96.9 m | -36.1 m | 28.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -19.36 | -18.45 | -24.18 | -1.53 | -0.49 | -0.18 | 0.11 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | -0.0% | -9.5% | -25.9% | -38.6% | -12.1% | -4.2% | 3.1% |
| Free cash flow | unavailable | -16.5 m | -20.8 m | 30.4 m | 5.2 m | 58.1 m | 50.3 m | 106.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 412.3 m USD
- Financial debt
- 444.7 m USD
- Net debt
- 32.4 m USD
- Equity
- 1.9 bn USD
- Total assets
- 3.6 bn USD
- Debt / equity
- 0.23x
- Current ratio
- 2.83x
- ROE
- 1.7%
- ROA
- 0.9%
- FCF margin
- 11.6%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 478.2 m | 611.6 m | 717.8 m | 800.9 m | 860.8 m | 925.4 m | SEC (XBRL)· 19 Feb 2026verified |
| Cost of revenue | 281.2 m | 359.8 m | 407.7 m | 444.5 m | 461.1 m | 486.8 m | SEC (XBRL)· 19 Feb 2026verified |
| Gross profit | 197.0 m | 251.8 m | 310.1 m | 356.4 m | 399.7 m | 438.6 m | SEC (XBRL)· 19 Feb 2026verified |
| Research & development | 15.9 m | 29.4 m | 30.3 m | 31.7 m | 35.0 m | 38.9 m | SEC (XBRL)· 19 Feb 2026verified |
| SG&A | 158.1 m | 211.2 m | 362.3 m | 340.1 m | 341.1 m | 348.2 m | SEC (XBRL)· 19 Feb 2026verified |
| Operating income | 23.0 m | 11.2 m | -297.8 m | -21.9 m | 24.8 m | 51.5 m | SEC (XBRL)· 19 Feb 2026verified |
| Depreciation & amortisation | 68.4 m | 83.6 m | 174.5 m | 162.8 m | 150.4 m | 138.1 m | SEC (XBRL)· 19 Feb 2026verified |
| EBITDA | 91.4 m ≈ | 94.8 m ≈ | -123.3 m ≈ | 140.9 m ≈ | 175.2 m ≈ | 189.6 m ≈ | SEC (XBRL)· 19 Feb 2026derived |
| Interest expense | — | — | — | 61.9 m | 57.9 m | 42.2 m | SEC (XBRL)· 19 Feb 2026verified |
| Pre-tax income | -45.5 m | -164.3 m | -306.6 m | -105.3 m | -33.9 m | 32.7 m | SEC (XBRL)· 19 Feb 2026verified |
| Income tax | -265.9 k | -5.9 m | -18.2 m | -6.6 m | 2.7 m | 2.9 m | SEC (XBRL)· 19 Feb 2026verified |
| Net income | -45.3 m | -158.4 m | -276.9 m | -96.9 m | -36.1 m | 28.8 m | SEC (XBRL)· 19 Feb 2026verified |
| Diluted EPS | -18.45 | -24.18 | -1.53 | -0.49 | -0.18 | 0.11 | SEC (XBRL)· 19 Feb 2026verified |
| Weighted average diluted shares | — | — | 181.1 m | 196.4 m | 205.0 m | 261.2 m | SEC (XBRL)· 19 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 108.7 m | 84.0 m | 73.5 m | 128.8 m | 175.2 m | 412.3 m | SEC (XBRL)· 19 Feb 2026verified |
| Receivables | — | 157.4 m | 171.2 m | 172.3 m | 177.7 m | 181.6 m | SEC (XBRL)· 19 Feb 2026verified |
| Inventories | — | 123.6 m | 143.3 m | 144.1 m | 133.2 m | 152.6 m | SEC (XBRL)· 19 Feb 2026verified |
| Current assets | 982.4 k | 453.4 m | 480.6 m | 538.6 m | 594.7 m | 893.7 m | SEC (XBRL)· 19 Feb 2026verified |
| Property, plant & equipment, net | — | 124.0 m | 124.3 m | 134.5 m | 146.3 m | 154.9 m | SEC (XBRL)· 19 Feb 2026verified |
| Goodwill | — | 1.7 bn | 1.4 bn | 1.4 bn | 1.4 bn | 1.9 bn | SEC (XBRL)· 19 Feb 2026verified |
| Intangibles (excl. goodwill) | — | 806.9 m | 650.4 m | 538.8 m | 411.6 m | 606.3 m | SEC (XBRL)· 19 Feb 2026verified |
| Total assets | 751.3 m | 3.1 bn | 2.7 bn | 2.7 bn | 2.6 bn | 3.6 bn | SEC (XBRL)· 19 Feb 2026verified |
| Accounts payable | 965.4 k | 59.4 m | 67.7 m | 58.7 m | 56.5 m | 57.4 m | SEC (XBRL)· 19 Feb 2026verified |
| Short-term debt | — | 3.9 m | 5.3 m | 1.2 m | 1.2 m | 1.6 m | SEC (XBRL)· 19 Feb 2026verified |
| Long-term debt | — | 806.8 m | 801.5 m | 684.7 m | 685.2 m | 443.1 m | SEC (XBRL)· 19 Feb 2026verified |
| Current liabilities | 73.0 m | 221.0 m | 244.3 m | 265.7 m | 263.4 m | 316.1 m | SEC (XBRL)· 19 Feb 2026verified |
| Total liabilities | 99.3 m | 1.3 bn | 1.3 bn | 1.2 bn | 1.1 bn | 1.7 bn | SEC (XBRL)· 19 Feb 2026verified |
| Equity | -733.4 m | 1.8 bn | 1.5 bn | 1.6 bn | 1.6 bn | 1.9 bn | SEC (XBRL)· 19 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -945.4 k | 53.6 m | 39.4 m | 95.2 m | 99.1 m | 143.3 m | SEC (XBRL)· 19 Feb 2026verified |
| Capex | 19.9 m | 23.2 m | 34.2 m | 37.1 m | 48.8 m | 36.4 m | SEC (XBRL)· 19 Feb 2026verified |
| Free cash flow | -20.8 m ≈ | 30.4 m ≈ | 5.2 m ≈ | 58.1 m ≈ | 50.3 m ≈ | 106.9 m ≈ | SEC (XBRL)· 19 Feb 2026derived |
| Investing cash flow | -75.6 m | -313.3 m | -39.5 m | -64.7 m | -43.7 m | -694.6 m | SEC (XBRL)· 19 Feb 2026verified |
| Financing cash flow | 751.4 m | 239.0 m | -7.0 m | 22.6 m | -3.3 m | 775.9 m | SEC (XBRL)· 19 Feb 2026verified |
| Share repurchases | — | 0 | 0 | 0 | 0 | 49.6 m | SEC (XBRL)· 19 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 65 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 336.9 m USD
Key indicators
Coverage and freshness
Score by group
- Balance sheet70
- Valuation64
- Quality48
- Growth74
- Returns100
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 4.45 – 478.17 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)227.71 – 478.17 (Mid 307.13)WACC 6.6% · starting FCFF 199.9 m USD · terminal value share of EV 83%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: no growth between −30% and +40% justifies the price
- Peers: EV/EBITDAunavailable · not enough peers
- Peers: P/E4.45 – 6.26 (Mid 4.69)3 companies used · median multiple 41.6x · quartiles 39.4x – 55.5xONTO, ROK, TMO
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 65/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 3.0% | 7 (on a fixed band) | 12% |
| Net margin · Quality | 2.7% | 63 (vs peers) | 7% |
| FCF conversion · Quality | 579.3% | 100 (on a fixed band) | 7% |
| Revenue CAGR 3Y · Growth | 8.8% | 74 (on a fixed band) | 10% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 0.2x | 100 (on a fixed band) | 12% |
| Interest coverage · Balance sheet | 1.5x | 0 (on a fixed band) | 7% |
| Current ratio · Balance sheet | 3.0x | 100 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 159.4x | 0 (on a fixed band) | 12% |
| EV/EBITDA · Valuation | 1.7x | 100 (on a fixed band) | 12% |
| FCF yield · Valuation | 49.9% | 100 (on a fixed band) | 10% |
| Shareholder yield (distributions) · Returns | 28.7% | 100 (on a fixed band) | 7% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet70/100 · 3/3 factors with a value
- Growth· partial74/100 · 1/2 factors with a value
- Quality48/100 · 3/3 factors with a value
- Returns· partial100/100 · 1/2 factors with a value
- Valuation64/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Mirion Technologies, Inc. (MIR). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 925.4 m USD in 2025; YoY growth 7.5%; net margin 2.7%; ROE 1.6%; net debt/EBITDA 0.2x.
The estimated value range is 116.08–242.21 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 155.91 USD, the price of 17.97 USD leaves a potential of 767.6% (value / price − 1) and a margin of safety of 88.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 65/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 579.3%
- Revenue CAGR 3Y: 8.8%
- Net debt / EBITDA: 0.2x
- Current ratio: 3.0x
- EV/EBITDA: 1.7x
- FCF yield: 49.9%
- Shareholder yield (distributions): 28.7%
- The price is below the estimated value range
What contradicts it
- ROIC: 3.0%
- Interest coverage: 1.5x
- P/E (TTM): 159.4x
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): EPS CAGR 3Y, Payout ratio (FCF).
Versus the vertical median
Measuring & Controlling Devices, NEC (SIC 3829) · same industry (4-digit SIC) · compared with 9 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific Inc. | 261.6 bn | 37.3 | 13.4% | 14.9% | +3.9% | +20% / +42% |
| ROKRockwell Automation, Inc. | 49.3 bn | 41.6 | 34.5% | 13.4% | +0.9% | +12% / +61% |
| TRMBTrimble Inc. | 12.4 bn | — | -2.9% | -4.1% | −2.6% | −33% / +17% |
| ONTOOnto Innovation Inc. | 9.1 bn | 69.4 | 6.8% | 11.8% | unavailable | +29% / +31% |
| MIRMirion Technologies, Inc. | 336.9 m | 159.4 | 1.6% | 2.7% | +7.5% | −35% / +119% |
| OWLTOwlet, Inc. | 132.4 m | — | — | -7.7% | +35.4% | −66% / −10% |
| GEOSGeospace Technologies Corp | 51.0 m | — | -34.4% | -43.1% | −18.3% | −70% / −67% |
| BCHTBirchtech Corp. | 28.9 m | — | -134.4% | -21.7% | +1.3% | −75% / −78% |
| NIKINiki BioSolutions, Inc. | — | — | -6.2% | — | −66.7% | −87% / −90% |
| QSIQuantum-Si Incorporated | — | — | -49.1% | -6,138.3% | −20.3% | −9% / −20% |
1- and 3-year price returns: for MIR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 152.06 Total return 746% · Per year 746% | 268.30 Total return 1,393% · Per year 1,393% | 403.39 Total return 2,145% · Per year 2,145% |
| 3 years | 160.72 Total return 794% · Per year 108% | 317.81 Total return 1,669% · Per year 161% | 522.75 Total return 2,809% · Per year 208% |
| 5 years | 169.88 Total return 845% · Per year 57% | 376.46 Total return 1,995% · Per year 84% | 677.42 Total return 3,670% · Per year 107% |
- Exit P/E± 79.45
- Net margin± 55.62
- Annual revenue growth± 43.83
- Annual dilution± 4.67
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 10-Q (28 Oct 2026), 8-K (27 Oct 2026 · results).
In brief
Mirion Technologies is a global provider of products, services and software for radiation detection, measurement and monitoring, active in nuclear power, medicine and defense. Revenue grew 19.7% in the second quarter of 2026, in a setting where nuclear demand is increasingly linked to data centers and energy security. Fiscal 2025 revenue was 925.4 million USD 13.
SWOT
Strengths
- The company has a large installed base that generates recurring revenue through replacements and services 1.
- A history of over six decades and product qualifications give it credibility in regulated sectors 1.
- A complementary portfolio, strengthened by recent acquisitions, allows cross-selling between segments 1.
Weaknesses
Opportunities
Risks
- Fixed-price contractsmedium
Costs can exceed estimates in long-term projects, and price escalation clauses do not always cover inflation 1.
- Geopolitical exposurehigh
Conflicts, sanctions and trade tensions can affect international operations and customer orders 12.
- Cost of debtmedium
Higher interest rates have increased debt service costs, and rates can influence financial results 1.
- Integration of acquisitionsmedium
Realizing synergies from recent acquisitions depends on successful integration, which is not assured 13.
- Public budgetslow
Government and hospital customers may reduce spending, which could delay orders 12.
Investment thesis
What would need to be true (bull case)
- If demand for nuclear energy keeps growing, the company's installed base could generate solid recurring revenue 1.
- Rising orders and backlog in the first half of 2026 show that product demand could support growth 23.
- Expanding margins and adjusted cash flow, if sustained, could support better results 3.
What to watch
- Delivery of the 2026 guidance on revenue and Adjusted EBITDA2026
- Development of orders and backlog in the second halfQ3 2026
- Impact of the Paragon and Certrec acquisitions on marginsnext 10-K
- Evolution of competition and order volume in ChinaQ4 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 10-Q (28 Oct 2026), 8-K (27 Oct 2026 · results).
The business
Mirion describes its activity as centered on protection against ionizing radiation, with more than 60 years of history including predecessor companies 1. The company is organized into two segments: Nuclear & Safety, which serves nuclear power plants, laboratories and the defense industry, and Medical, which covers cancer care, nuclear medicine and occupational dosimetry 1. Headquarters are in Atlanta, with operations in several European countries, Canada, China and Japan 1.
Market context
According to the company, the nuclear power market is viewed as positive, as the International Atomic Energy Agency raised its annual projections for the fifth year in a row 1. The company also cites demand linked to data centers and artificial intelligence, which could support new investment in nuclear capacity 1. The medical market grows on the back of an aging population and rising cancer incidence 1.
The company estimates that the existing reactor base, with an average age of more than 40 years in the US, could generate repeated cycles of equipment replacement and upgrades 1. Dosimetry for medical staff could also grow as government agencies outsource services 1.
Trends
- Renewed interest in nuclear energytailwind
Governments and investors increasingly back nuclear as a low-emission source, and dormant plants are being restarted to meet data center demand 1. If this trend strengthens, demand for monitoring products could rise.
- Growing demand for radiation therapytailwind
An aging population and rising cancer cases support demand for quality assurance in radiation therapy and for nuclear medicine 12.
- Local competition in Chinaheadwind
The company flags rising competition from local firms and volume-based procurement policies, which have affected or could affect orders in China 2.
- Geopolitical and trade tensionsmixed
US-China relations, Middle East conflicts and tariffs can create inflation, supply chain problems and delays in customer projects 12.
Competitive position
Mirion operates in highly regulated markets where customers prefer suppliers with a proven track record, which makes entry harder for new competitors 1. The company says its installed base and long customer relationships give it an edge, but the sources do not state a numerical market share 1.
In Medical, competition from local firms in China has increased, and volume-based procurement pressure could affect margins 2. The sources analyzed do not list a full set of competitors.
- Local suppliers in China
Local companies have intensified competition in the Chinese medical market, according to the company 2.
- Local suppliers in China
Local companies have intensified competition in the Chinese medical market, according to the company 2.
- Local suppliers in China
Local companies have intensified competition in the Chinese medical market, according to the company 2.
- Local suppliers in China
Local companies have intensified competition in the Chinese medical market, according to the company 2.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report28 Oct 2026
- Current report27 Oct 2026Results of operations · Financial statements and exhibits
- Current report31 Aug 2026Other events · Financial statements and exhibits
- Quarterly report29 Jul 2026
- Current report28 Jul 2026Results of operations · Financial statements and exhibits
- Current report02 Jul 2026Departure or appointment of officers · Financial statements and exhibits
- Current report14 May 2026Shareholder vote · Financial statements and exhibits
- Quarterly report29 Apr 2026
- Current report28 Apr 2026Results of operations · Financial statements and exhibits
- Current report13 Apr 2026Departure or appointment of officers · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Mirion Technologies, Inc. · 19 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Mirion Technologies, Inc. · 29 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Mirion Technologies, Inc. · 28 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.